Hanmi Pharm to develop obesity drug customized for S.Korean

S.Korean pharmaceutical company submits IND for clinical phase 3 application of GLP-1 class Epeglenatide to domestic authority

Hanmi Pharm to develop obesity drug customized for S.Korean
Ji-Hyun Lee 2
2023-07-31 17:04:29 bluesky@hankyung.com
Bio & Pharma

South Korea's Hanmi Pharmaceutical Co. plans to develop the GLP-1 class "Epeglenatide," which it received as a technology return from Sanofi S.A., into a personalized obesity drug for domestic.

This decision is based on the assessment that there is a market potential for developing a therapeutic agent targeting domestic obese patients with a body mass index (BMI) of 25 or higher.

With global companies launching successive GLP-1 drugs and experiencing soaring prices and scarcity, it is expected that expanding the domestic GLP-1 market will be profitable.

Hanmi Pharm announced Monday that it had submitted on July 28 an investigational new drug (IND) application for clinical phase 3 of the obesity drug Epeglenatide to the Ministry of Food and Drug Safety.

The company has been developing Epeglenatide, applying the Long Acting Protein/Peptide Discovery (LAPSCOVERY) technology, as a metabolic disorder treatment administered once a week. If it receives regulatory approval as an obesity drug, it plans to expedite commercialization.

Epeglenatide was a substance whose development rights were transferred to the French pharmaceutical company Sanofi in 2015 in a mega-contract worth up to 5 trillion won ($3.9 billion). However, Sanofi returned the development rights to Hanmi Pharm in June 2020.

This decision was made because the market potential weakened due to delays in Epeglenatide's development and the release of similar GLP-1 therapies such as Novo Nordisk's Saxenda and Ozempic.

After the agreement with Hanmi Pharm, Sanofi conducted five global phase 3 clinical trials involving about 6,000 metabolic disorder patients. In June 2021, the French drug maker presented the clinical results orally at the American Diabetes Association (ADA) and published the research results in The New England Journal of Medicine. Hanmi Pharm's explanation was that this confirmed the drug's potential.

According to the South Korean company, Epeglenatide was proven to reduce the risk of major cardiovascular and renal events in a large-scale cardiovascular outcome trial (CVOT) involving over 4,000 patients.

Considering these circumstances, Hanmi Pharmaceutical concluded that Epeglenatide could be optimized for Koreans with obesity standards (BMI 25kg/m2) as a "Korean-customized GLP-1." While global companies are introducing GLP-1 obesity drugs one after another, most of them are tailored for severely obese patients in Western countries.

"It means developing the first GLP-1 obesity drug developed by a Korean pharmaceutical company through independent technology, as a 'Korean-customized obesity drug' that reflects the physique and weight of Koreans," a company source said.

Write to Ji-Hyun Lee at bluesky@hankyung.com

Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA

Hanmi Pharm's  Efinopegdutide gets Fast Track Designation from FDA

Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean pharmaceutical company Hanmi Pharmaceutical Co., was granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatme

Hanmi Pharmaceutical reports record-high revenue in 2022

Hanmi Pharmaceutical reports record-high revenue in 2022

South Korea's Hanmi Pharmaceutical Co. last year saw record-high performance thanks to its self-developed drugs, surpassing its previous best year of 2015, when half of sales came from technology export fees for new drug candidates.Considered a prestigious brand of incrementally modified drugs

Spectrum to push back launch date of Hanmi-developed drug Poziotinib

Spectrum to push back launch date of Hanmi-developed drug Poziotinib

An aerial view of Hanmi Pharmaceutical's headquarters  Hanmi Pharmaceutical Co. announced Friday that California-based Spectrum Pharmaceuticals Inc. received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA), which will delay a new drug’s release date.&n

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Rolontis, a neutropenia agent, will be sold in the US under the Rolvedon brand South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has obtained marketing approval from the US Food and Drug Administration.T

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

Rolontis, a neutropenia agent developed by Hanmi Pharmaceutical The US Food and Drug Administration has begun reviewing a medicine developed by South Korea’s Hanmi Pharmaceutical Co. for marketing authorization of the white blood cell disease treatment.The FDA will complete its review of

(* comment hide *}